Bestcan

Bestcan is a clinical-stage biotechnology company based in China that specializes in the development and manufacturing of recombinant vaccines. The company's primary focus is on human papillomavirus (HPV) prevention, with a robust pipeline that includes a 9-valent HPV vaccine currently in Phase 3 clinical trials. Bestcan utilizes a proprietary recombinant protein expression platform to produce high-quality virus-like particles (VLPs) for its vaccine candidates. Headquartered in Beijing, the company aims to address the high demand for affordable and effective cervical cancer prevention in the Chinese market. Bestcan's integrated approach spans from early-stage research to large-scale GMP manufacturing.